Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Naz Rahman reaffirmed a Buy rating on Vertex Pharmaceuticals with a $575 price target, citing the Crinetics acquisition as a key driver for revenue diversification into rare endocrine diseases. The deal adds commercial and pipeline assets expected to reach $5 billion in peak sales by 2029. Barclays also maintained a Buy rating with a $615 target. VRTX stock rose 6.12% over six months.
Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Vertex Pharmaceuticals, retaining the price target of $575.00.
55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Naz Rahman has given his Buy rating due to a combination of factors, including Vertex’s strategic acquisition of Crinetics and the resulting broadening of its revenue base beyond cystic fibrosis. By adding Crinetics’ commercial drug Palsonify and the Phase 3–ready atumelnant, Vertex gains meaningful exposure to rare endocrine diseases with once-daily oral therapies that could be differentiated versus existing injectables or twice-daily options.
Rahman also points to management’s view that the acquired assets could collectively reach roughly $5 billion in peak sales, with the deal expected to become accretive to non-GAAP operating income by 2029. Given this portfolio diversification, the long-term growth potential, and only a modest anticipated impact on 2026 financials, he maintains a Buy rating and keeps his price target unchanged at $575.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $615.00 price target.
VRTX’s price has also changed slightly for the past six months – from $469.680 to $498.430, which is a 6.12% increase.